Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ).
Lumos Diagnostics Holdings Ltd. has announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to conduct a clinical study aimed at expanding the use of its FebriDx® diagnostic test to pediatric patients aged 2-12 years in CLIA-waived settings. This study, supported by a $6.198 million funding package from BARDA, is expected to significantly increase Lumos’ market reach by potentially expanding its U.S. total addressable market 15-fold to over $1 billion, providing access to 270,000 clinical sites and covering 80 million annual acute respiratory consultations.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics specializes in rapid, point-of-care diagnostic test technology to aid healthcare professionals in accurately diagnosing and managing medical conditions. The company offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms, focusing on infectious and inflammatory diseases.
Average Trading Volume: 6,420,680
Technical Sentiment Signal: Buy
Current Market Cap: A$94.19M
Learn more about LDX stock on TipRanks’ Stock Analysis page.